ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

$40.40  -1.65 (-3.92%)
As of 04/09/2021 15:59:54 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/25/2014
Outstanding shares:  136,772,417
Average volume:  1,182,503
Market cap:   $5,528,341,095
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00650F109
ISIN:        US00650F1093
Sedol:      BJ5FZ74
Valuation   (See tab for details)
PE ratio:   -37.81
PB ratio:   7.49
PS ratio:   56.19
Return on equity:   -19.67%
Net income %:   -148.63%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy